PYPD · PolyPid Ltd.

PolyPid's Q1 2026 results reflect a pivotal transition from late-stage development to regulatory submission and commercial preparation, as R&D expenses declined 5% to $5.8 million due to SHIELD II Phase 3 trial completion, partially offset by rises in G&A to $1.6 million and marketing to $0.4 million, yielding a narrower net loss of $7.7 million or ($0.35) per share versus prior year. CEO Dikla Czaczkes Akselbrad highlighted the NDA initiation for D-PLEX₁₀₀ on March 30 under rolling review, with CMC and nonclinical modules submitted and clinical data imminent, bolstered by a $4.3 million PDUFA fee waiver conserving cash for commercialization. U.S. partnership talks advanced to late stages, while EMA meetings are set for Q2 ahead of Q3 MAA submission. New SHIELD II data at SIS and ESCMID congresses showed 64% relative risk reduction in severe wound infections and 30-day doxycycline release, reinforcing clinical value. Balance sheet shows $10.9 million cash post-$2 million burn, aided by $4 million warrant exercises; full $0.8 million debt repayment in May eliminates liabilities. Cash runway extends into H2 2026 through NDA completion, PDUFA in Q1 2027, and potential partnership, positioning PolyPid for approval and launch.